obesity drug market – The Milli Chronicle

Friday, November 14, 2025

Latest:

Saudi beekeepers harvest highly valued Sidr honey in Najran region
Saudi Arabia’s Yemen reconstruction program signs power deal, expands major infrastructure projects
Saudi doctors successfully separate Jamaican conjoined twins in complex surgery
Obama-Appointed Judge’s Dissent May Strengthen Trump’s Case in Supreme Court Tariff Battle
U.S. Judge Declines to Sanction Buchalter Over AI-Generated Case Citations in Court Filing

Factual Version of a Story

Novo Nordisk and Eli Lilly Reject Claims of Partnership with Mangoceuticals on Obesity Drugs

Novo Nordisk and Eli Lilly clarify that they have no collaboration or special arrangement with telehealth firm Mangoceuticals, following misleading

Pfizer secures $10 billion Metsera deal after Novo Nordisk withdraws

Pfizer’s $10 billion acquisition of Metsera marks a major victory for the U.S. pharmaceutical giant, strengthening its position in the

Pfizer Strengthens Its Bid for Metsera, Reinforces Commitment to Innovation in Obesity Treatment

Pfizer’s strategic move to revise its bid for Metsera underscores its dedication to advancing next-generation obesity therapies and fostering competition